Table 6.
mitomiR-based therapeutics and targeting mechanisms in preclinical study of TNBC.
| Approach/reagent | Effecting mitomiR | Experimental model | PMID | Reference |
|---|---|---|---|---|
| Metabolic reprogramming | ||||
| siRNA-circPVT1 | ↑miR-29a | In vivo, in vitro | 33223849 | Wang et al., 2020 [28] |
| Lentivirus-miR-128 | ↑miR-128 | In vivo, in vitro | 29116653 | Xiao et al., 2018 [33] |
| Small molecule (metformin) | ↓miR-21 | In vitro, in vivo | 28698800 | Pulito et al., 2017 [48] |
| Apoptosis | ||||
| Nanoparticle-loaded miR-34a | ↑miR-34a | In vivo, ex ovo, in vitro | 32319481 | Ahir et al., 2020 [54] |
| Nanoparticle-loaded anti-miR-10b | ↓miR-10b | In vivo, ex ovo, in vitro | 32319481 | Ahir et al., 2020 [54] |
| Cisplatin+thiosemicarbazone compound 4 | ↑miR-125a, ↑miR-181a | In vitro | 31541355 | Majzoub et al., 2019 |
| shRNA-lncCAMTA1 | ↑miR-20b | In vitro | 28550685 | Lu et al., 2018 [59] |
| Anti-miR-221 | ↓miR-221 | In vitro | 26503209 | Ye et al., 2016 [80] |
| Redox signaling | ||||
| Natural product (ursolic acid) | ↓miR-499a | Ex ovo, in vitro | 33278391 | Manda et al., 2020 [76] |
| Physical agent (ultrasound) | ↑miR-200c | In vitro | 32313093 | Shi et al., 2020 [85] |
| Natural product (parthenolide) | ↑miR-29b | In vitro | 31313842 | De Blasio, 2019 [84] |
| shRNA-LINC00963 | ↑miR-324 | In vitro, in vivo | 31751910 | Zhang et al., 2019 [52] |
| Adenovirus-MDA-7 | ↓miR-221 | In vitro, in vivo | 30842276 | Pradhan et al., 2019 [82] |
| CuO-Nw-FA | ↑miR-425 | In vivo, ex ovo, in vitro | 26520043 | Ahir et al., 2016 [83] |
| Histone deacetylase inhibitor (SAHA) | ↑miR-200a | In vitro | 21926171 | Eades et al., 2011 [51] |
| Mitochondrial calcium transport | ||||
| Exosome | ↑miR-4488 | In vivo, in vitro | 33067576 | Zheng et al., 2020 [74] |
“↑”: enhanced; “↓”: reduced; circPVT1: circular RNA PVT1; CuO-Nw-FA: copper oxide nanowire conjugated with folic acid; lncRNA: long noncoding RNA; MITF: melanogenesis-associated transcription factor; SAHA: suberoylanilide hydroxamic acid.